What are the limitations on the wider therapeutic use of phage?
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Bacterial resistance to antibiotics poses a serious health threat. Since research into new antibiotics is not progressing at the same rate as the development of bacterial resistance, widespread calls for alternatives to antibiotics have been made. Phage therapy is an ideal alternative candidate to be investigated. However the success of phage therapy may be hampered by a lack of investment support from large pharmaceutical companies, due to their narrow spectrum of activity in antibiotics, very large costs associated with clinical trials of the variety of phages needed, and regulatory requirements remaining unclear. Intellectual property is difficult to secure for therapeutic phage products for a variety of reasons, and patenting procedures vary widely between the US and the EU. Consequently, companies are more likely to invest in phage products for decontamination or veterinary use, rather than clinical use in humans. Some still raise questions as to the safety of phage therapy overall, suggesting the possibility of cytotoxicity and immunogenicity, depending on the phage preparation and route. On the other hand, with patients dying because of infections untreatable with conventional antibiotics, the question arises as to whether it is ethical not to pursue phage therapy more diligently. A paradigm shift about how phage therapy is perceived is required, as well as more rigorous proof of efficacy in the form of clinical trials of existing medicinal phage products. Phage therapy potential may be fulfilled in the meantime by allowing individual preparations to be used on a named-patient basis, with extensive monitoring and multidisciplinary team input. The National Health Service and academia have a role in carrying out clinical phage research, which would be beneficial to public health, but not necessarily financially rewarding.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of Biomedical Ethics
(2012) · Thieves of Virtue · doi:10.7551/mitpress/9079.003.0009 · Cited by 13,453
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Trends in antimicrobial drug development: Implications for the future
Spellberg, B., Powers, J. H., Brass, E. P., Miller, L. G., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/420937 · Cited by 867 · cited 1×
“For these reasons some large pharmaceutical companies have indicated that they are limiting or entirely aban-doning anti-infective research, except for anti-HIV agents, 40 which are more profitable.”
Cited by
Phage Therapy in the Postantibiotic Era
Gordillo Altamirano, F. L., & Barr, J. J. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00066-18 · Cited by 1,180
Alkaloids: An overview of their antibacterial, antibiotic-enhancing and antivirulence activities
Cushnie, T. P. T., Cushnie, B., & Lamb, A. J. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.06.001 · Cited by 894
Gut Microbiota and Colonization Resistance against Bacterial Enteric Infection
Ducarmon, Q. R., Zwittink, R. D., Hornung, B. V. H., van Schaik, W., Young, V. B., & Kuijper, E. J. (2019) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00007-19 · Cited by 566
“Therapeutic use in humans is not yet performed on a wide scale in the Western world, as sufficient evidence for their safety and efficacy is still lacking (81).”
BackgroundThe Biological Activity of Natural Alkaloids against Herbivores, Cancerous Cells and Pathogens
Thawabteh, A., Juma, S., Bader, M., Karaman, D., Scrano, L., Bufo, S., & Karaman, R. (2019) · Toxins · doi:10.3390/toxins11110656 · Cited by 334
Revisiting phage therapy: new applications for old resources
Nobrega, F. L., Costa, A. R., Kluskens, L. D., & Azeredo, J. (2015) · Trends in Microbiology · doi:10.1016/j.tim.2015.01.006 · Cited by 310
Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review
Kakasis, A., & Panitsa, G. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.09.004 · Cited by 261
Positive and negative aspects of bacteriophages and their immense role in the food chain
Ranveer, S. A., Dasriya, V., Ahmad, M. F., Dhillon, H. S., Samtiya, M., Shama, E., Anand, T., Dhewa, T., Chaudhary, V., Chaudhary, P., et al. (2024) · npj Science of Food · doi:10.1038/s41538-023-00245-8 · Cited by 221
“Furthermore, preparing phages for medicinal application is challenging, and not all of the issues that are strictly interrelated with phage biology have been resolved 6,119,120 .”
Alves, D. R., Gaudion, A., Bean, J. E., Perez Esteban, P., Arnot, T. C., Harper, D. R., Kot, W., Hansen, L. H., Enright, M. C., & Jenkins, A. T. A. (2014) · Applied and Environmental Microbiology · doi:10.1128/aem.01789-14 · Cited by 182
Exploiting gut bacteriophages for human health
Dalmasso, M., Hill, C., & Ross, R. P. (2014) · Trends in Microbiology · doi:10.1016/j.tim.2014.02.010 · Cited by 179
Engineering Bacteriophages as Versatile Biologics
Kilcher, S., & Loessner, M. J. (2019) · Trends in Microbiology · doi:10.1016/j.tim.2018.09.006 · Cited by 171
(2023) · doi:10.1016/j.mtbio.2023.100612 · Cited by 71
The applications of animal models in phage therapy: An update
Mehmood Khan, F., Manohar, P., Singh Gondil, V., Mehra, N., Kayode Oyejobi, G., Odiwuor, N., Ahmad, T., & Huang, G. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2175519 · Cited by 32
Teymouri, S., Yousefi, M. H., Heidari, S., Farokhi, S., Afkhami, H., & Kashfi, M. (2025) · Molecular Biology Reports · doi:10.1007/s11033-024-10163-x · Cited by 11
“Its long history of application indicates a significant level of safety [ 37 , 38 ].”
Metadata
- Authors
- Henein, A.
- Venue
- Bacteriophage
- Publisher
- Informa UK Limited
- Published
- 2013-04
- Volume
- 3
- Issue
- 2
- Pages
- e24872
- ISSN
- 2159-7073 (ISSN-L)
- 2159-7081
- OpenAlex
- W2041923277
- Cited by
- 104
- References
- 3
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.